Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018

It is unclear whether survival in diffuse large B-cell lymphoma (DLBCL) continues to increase in an era where rituximab-containing chemotherapy reigns for almost two decades. Therefore, we evaluated trends in primary therapy and relative survival (RS) among Dutch DLBCL patients diagnosed between 198...

Descripción completa

Detalles Bibliográficos
Autores principales: Durmaz, Müjde, Visser, Otto, Posthuma, Eduardus F. M., Brouwer, Rolf E., Issa, Djamila E., de Jong, Daphne, Lam, King H., Blijlevens, Nicole M. A., Zijlstra, Josée M., Chamuleau, Martine E. D., Lugtenburg, Pieternella J., Kersten, Marie José, Dinmohamed, Avinash G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907354/
https://www.ncbi.nlm.nih.gov/pubmed/35264598
http://dx.doi.org/10.1038/s41408-022-00637-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907354/
https://www.ncbi.nlm.nih.gov/pubmed/35264598
http://dx.doi.org/10.1038/s41408-022-00637-1

Ejemplares similares